Lutetium lu 177 dotatate Alternatives Compared
| Lutetium lu 177 dotatate | Lanreotide | Everolimus |
|
|---|
| Lutetium lu 177 dotatate | Lanreotide | Everolimus |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Neuroendocrine Carcinoma. Lutetium lu 177 dotatate may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Neuroendocrine Carcinoma, Carcinoid Syndrome, Acromegaly. Lanreotide may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Neuroendocrine Carcinoma, Renal Angiomyolipoma, Breast Cancer, Organ Transplant - Rejection Prophylaxis, Tuberous Sclerosis Complex, Brain Tumor, Pancreatic Cancer, Renal Cell... View more |
Related suggestions Neuroendocrine Carcinoma
|
|||||||||||||||
| More about Lutetium lu 177 dotatate | More about Lanreotide | More about Everolimus | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Lanreotide has an average rating of 8.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Everolimus has an average rating of 5.6 out of 10 from a total of 29 ratings on Drugs.com. 46% of reviewers reported a positive effect, while 38% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
Lower cost generic |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Lanreotide prices |
View all Everolimus prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Lutathera | Somatuline Depot | Afinitor, Afinitor Disperz, Torpenz, Zortress | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
71 hours |
720 hours |
35 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 231 drugs are known to interact with Lutetium lu 177 dotatate:
|
A total of 158 drugs are known to interact with Lanreotide:
|
A total of 529 drugs are known to interact with Everolimus:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
January 26, 2018 |
N/A |
March 30, 2009 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.